Taylor Andrew Lawrence 4

What Happened

• Taylor Andrew Lawrence, Chief Financial Officer of Orchestra BioMed (OBIO), was granted 181,000 restricted stock units (RSUs) on 2026-02-12. The award was reported on Form 4 as an acquisition via grant (code A) at $0.00 per share (no cash paid at grant). Each RSU represents a contingent right to one share of common stock upon vesting.

Key Details

• Transaction date: 2026-02-12; Filing date: 2026-02-13 (filed timely).
• Grant amount and price: 181,000 RSUs at $0.00 (award/grant).
• Vesting: Four equal tranches of 25% (45,250 RSUs each) vest over time per footnote: 18, 24, 30 and 36 months after the issue date (Feb 12, 2026), subject to continuous service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant of RSUs.

Context

• RSUs are a form of compensation/retention award, not an immediate purchase or sale. No shares are delivered until each tranche vests, and value to the holder depends on Orchestra BioMed's share price at vesting.
• Such grants are common for executives and do not by themselves indicate a buy/sell signal; they reflect company compensation practices and retention incentives.